KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Total Debt (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Total Debt for 17 consecutive years, with $12.9 billion as the latest value for Q4 2025.

  • Quarterly Total Debt fell 8.47% to $12.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.9 billion through Dec 2025, down 8.47% year-over-year, with the annual reading at $12.9 billion for FY2025, 8.47% down from the prior year.
  • Total Debt hit $12.9 billion in Q4 2025 for Abbott Laboratories, roughly flat from $12.9 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $18.2 billion in Q1 2021 to a low of $12.9 billion in Q4 2025.
  • Historically, Total Debt has averaged $15.7 billion across 5 years, with a median of $16.0 billion in 2022.
  • Biggest five-year swings in Total Debt: grew 7.27% in 2021 and later fell 13.69% in 2024.
  • Year by year, Total Debt stood at $18.0 billion in 2021, then fell by 7.07% to $16.8 billion in 2022, then dropped by 12.48% to $14.7 billion in 2023, then decreased by 3.77% to $14.1 billion in 2024, then decreased by 8.47% to $12.9 billion in 2025.
  • Business Quant data shows Total Debt for ABT at $12.9 billion in Q4 2025, $12.9 billion in Q3 2025, and $13.4 billion in Q2 2025.